Skip to main content
Insights
/ Webinars

Activating BD&L and Open Innovation with MSD

MSD
Wed, Jun 04, 2025
17:00 CET | 11:00 EST
Activating BD&L and Open Innovation with MSD

Reserve your seat

First name
Last name
Business email
Company name
Job title
Which sector best reflects your role?
By submitting this form, you agree to receive email communications from Inpart as well as the storing and processing of your personal data by Inpart as detailed in the Privacy Statement. You may unsubscribe from these communications at any time.

With a broad focus across human and animal health, MSD’s BD&L teams are tasked with searching the world for cutting-edge science, regardless of therapeutic area or modality. In this webinar, Daniel Marshall, Director of Oncology Business Development at MSD, will join Inpart to explain how MSD integrates BD&L with Open Innovation and what it’s like to partner with one of the world’s largest pharma companies.

In the crucial weeks before BIO 2025, Daniel will offer strategies and tactics for early-stage biotechs and academic innovators seeking to connect with top pharma companies, as well as tips on how to get a foot in the door at the world’s largest partnering event.

Panelists

Daniel Marshall
Daniel Marshall
Director, Oncology Business Development, MSD

Join this webinar to learn:

  • The key components of MSD’s BD&L and Open Innovation strategies
  • What it's like to partner with a top global pharma company
  • How MSD works towards being a Partner of Choice
  • How to secure meetings with MSD and other top pharma companies at major conferences

About MSD

For more than 130 years, MSD (known as Merck & Co. in the United States and Canada) has delivered invaluable medicines and vaccines. The company aspires to be the premier research-intensive biopharmaceutical organization in the world—and today, it stands at the forefront of research, delivering innovative health solutions that advance the prevention and treatment of diseases in both people and animals.